EXELIXIS, INC.

Exelixis reported strong financial results for the second quarter and first six months of 2026. Net income for Q2 2026 increased to $212.05 million on total revenues of $628.69 million, driven by growth in net product revenues, primarily from CABOMETYX. The company also saw a significant increase in net cash provided by operating activities and continued its share repurchase program.

Exelixis reported strong financial results for the second quarter of 2026, with total revenues increasing to $628.7 million and GAAP diluted EPS rising to $0.82. The company also provided an update on its pipeline, including the FDA's acceptance of the New Drug Application for zanzalintinib in metastatic colorectal cancer with a PDUFA date set for December 3, 2026. However, Exelixis adjusted its full-year 2026 financial guidance, slightly lowering total and net product revenue expectations while also reducing R&D expense guidance. The company continued its stock repurchase program, completing a $750 million authorization and approving an additional $750 million.

Exelixis, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders voted to amend and restate the 2017 Equity Incentive Plan, which became effective immediately. Additionally, eleven directors were elected to the Board, and the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 1, 2027, was ratified. The advisory vote on the compensation of the company's named executive officers (Say on Pay) also received stockholder approval.

Exelixis reported strong financial results for the first quarter of 2026, with net income increasing significantly by 31.9% to $210.5 million and diluted EPS rising 43.6% to $0.79. Total revenues grew 10.0% to $610.8 million, driven by an 8.1% increase in net product revenues, primarily from CABOMETYX, and a 32.4% surge in collaboration revenues. The company also continued its share repurchase program, buying back $430.4 million of common stock, and recognized a $7.7 million commercial milestone payment from Takeda.

Exelixis announced its first quarter 2026 financial results, reporting total revenues of $610.8 million and GAAP diluted EPS of $0.79. Concurrently, the Board authorized a new stock repurchase program of up to an additional $750 million of common stock by December 31, 2027. The company also provided a corporate update, highlighting the FDA's acceptance of the New Drug Application for zanzalintinib in metastatic colorectal cancer and progress across its clinical development programs.